ImmuCell Q2 Profit Jumps as Margins Rise
(NASDAQ:ICCC) reported results for the three-month period ended June 30, 2025, on August 14, 2025, highlighting a sharp rebound in profitability with adjusted EBITDA of $1.43 million. Strategic updates included the completion of First Defense production capacity expansion and ongoing delays in FDA approval for Retain, along with an improved debt structure.
In this period, ImmuCell finalized its multi-year investment to expand production capacity, targeting the ability to support annual revenue of $30 million or more, removing prior supply bottlenecks. Backlog liquidation, inventory distribution rebuild, and a return to normal distribution channels followed supply disruptions caused by contamination events, which were resolved by Q2 2025.
This operational milestone shifts management focus from crisis recovery to growth, reducing a major operational risk that had impaired customer relationships and positioning the company to recapture lost business and drive future market share gains.
Source Fool.com
